

Stefan Steurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8766652/publications.pdf>

Version: 2024-02-01

122
papers

4,850
citations

186265

28
h-index

106344

65
g-index

126
all docs

126
docs citations

126
times ranked

10198
citing authors

#	ARTICLE	IF	CITATIONS
1	Dying of VOC-202012/01 "multimodal investigations in a death case of the SARS-CoV-2 variant. International Journal of Legal Medicine, 2022, 136, 193-202.	2.2	3
2	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 433-447.	2.8	11
3	Low incidence of colonic complications after severe Shiga toxin-producing E. coli O104:H4 infection. Zeitschrift Fur Gastroenterologie, 2022, 60, 1104-1110.	0.5	1
4	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. Laboratory Investigation, 2022, 102, 650-657.	3.7	5
5	Abstract P069: Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2022, , .		0
6	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Experimental and Molecular Pathology, 2022, 126, 104762.	2.1	15
7	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 2022, 89, 245-258.	3.8	15
8	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. Human Pathology, 2022, 126, 108-120.	2.0	4
9	Comparison of four diagnostic criteria for invasive pulmonary aspergillosis "A diagnostic accuracy study in critically ill patients. Mycoses, 2022, 65, 824-833.	4.0	6
10	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211065.	2.1	1
11	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10...399 Tissue Samples. Technology in Cancer Research and Treatment, 2021, 20, 153303382110433.	1.9	10
12	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biology and Medicine, 2021, 18, 245-255.	3.0	13
13	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	6.8	33
14	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Molecular Medicine, 2021, 27, 16.	4.4	32
15	Clonal expansion and activation of tissue-resident memory-like T _H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. Science Immunology, 2021, 6, .	11.9	125
16	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	1.4	3
17	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	1.9	12
18	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. <i>Biomedicines</i> , 2021, 9, 397.	3.2	42
20	Multi-scale fully convolutional neural networks for histopathology image segmentation: From nuclear aberrations to the global tissue architecture. <i>Medical Image Analysis</i> , 2021, 70, 101996.	11.6	52
21	Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer. <i>Aging</i> , 2021, 13, 14590-14603.	3.1	5
22	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. <i>Biomarker Research</i> , 2021, 9, 44.	6.8	30
23	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 1210-1217.	1.8	10
24	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
25	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0
26	Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators. <i>American Journal of Pathology</i> , 2021, 191, 1193-1208.	3.8	14
27	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. <i>Pathology Research and Practice</i> , 2021, 224, 153533.	2.3	3
28	Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness. <i>Cancer Investigation</i> , 2021, 39, 711-720.	1.3	6
29	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. <i>PeerJ</i> , 2021, 9, e11905.	2.0	4
30	Pattern of placental alkaline phosphatase (<sc>PLAP</sc>) expression in human tumors: a tissue microarray study on 12,381 tumors. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 577-589.	3.0	12
31	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. <i>Human Pathology</i> , 2021, 115, 19-36.	2.0	19
32	Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases. <i>Scientific Reports</i> , 2021, 11, 19342.	3.3	28
33	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151793.	1.3	11
34	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. <i>Medical Molecular Morphology</i> , 2021, 54, 156-165.	1.0	9
35	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. <i>Pathology Research and Practice</i> , 2021, 228, 153663.	2.3	11
36	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. <i>Diagnostics</i> , 2021, 11, 2351.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Quantitative analysis of submucosal excision depth in endoscopic resection for early Barrett's cancer. <i>Endoscopy</i> , 2021, , .	1.8	1
38	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 129-138.	4.6	19
39	High homogeneity of mismatch repair deficiency in advanced prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 745-752.	2.8	17
40	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2185-2196.	2.2	10
41	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. <i>Pathology and Oncology Research</i> , 2020, 26, 2709-2722.	1.9	7
42	Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 268-277.	3.9	1,954
43	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. <i>Disease Markers</i> , 2020, 2020, 1-10.	1.3	4
44	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 625-636.	2.8	6
45	Dying with SARS-CoV-2 infection – an autopsy study of the first consecutive 80 cases in Hamburg, Germany. <i>International Journal of Legal Medicine</i> , 2020, 134, 1275-1284.	2.2	361
46	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. <i>Molecular Medicine</i> , 2020, 26, 24.	4.4	5
47	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 421-430.	4.4	23
48	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. <i>Endocrine Pathology</i> , 2020, 31, 182-189.	9.0	15
49	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3997-4006.	1.5	20
50	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , 2020, 80, 1097-1107.	2.3	10
51	Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1043-1056.	4.2	10
52	ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. <i>Neuro-Oncology</i> , 2020, 22, 955-966.	1.2	36
53	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 488-495.	1.6	19
54	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 669-675.	1.4	24

#	ARTICLE	IF	CITATIONS
55	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. <i>Pathology</i> , 2020, 52, 421-430.	0.6	5
56	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. <i>Pathology International</i> , 2020, 70, 441-451.	1.3	8
57	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. <i>Oncotarget</i> , 2020, 11, 1007-1016.	1.8	14
58	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. <i>Neoplasia</i> , 2019, 21, 872-881.	5.3	5
59	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019, 18, 1497-1502.	1.8	7
60	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. <i>Tumor Biology</i> , 2019, 41, 101042831882481.	1.8	9
61	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 944.	2.6	4
62	Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. <i>Disease Markers</i> , 2019, 2019, 1-13.	1.3	47
63	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. <i>Cancer Biology and Medicine</i> , 2019, 16, 319.	3.0	2
64	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. <i>Disease Markers</i> , 2019, 2019, 1-6.	1.3	12
65	SNW1 is a prognostic biomarker in prostate cancer. <i>Diagnostic Pathology</i> , 2019, 14, 33.	2.0	7
66	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. <i>Oncology Letters</i> , 2019, 17, 3826-3834.	1.8	19
67	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 193.	2.6	24
68	Loss of CCAAT enhancer binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , 2019, 79, 302-311.	2.3	4
69	5q21 deletion is often heterogeneous in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 509-515.	2.8	4
70	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. <i>Aging</i> , 2019, 11, 7859-7879.	3.1	28
71	A nuclear shift of GSK3 β protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , 2019, 10, 1729-1744.	1.8	2
72	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , 2019, 10, 5439-5453.	1.8	22

#	ARTICLE	IF	CITATIONS
73	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. <i>Oncotarget</i> , 2019, 10, 7096-7111.	1.8	4
74	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. <i>Oncology Reports</i> , 2018, 39, 3-12.	2.6	50
75	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , 2018, 18, 37.	2.6	16
76	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 877-882.	2.2	26
77	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , 2018, 73, 674-683.	1.9	40
78	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. <i>BMC Cancer</i> , 2018, 18, 1209.	2.6	28
79	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. <i>BMC Cancer</i> , 2018, 18, 1106.	2.6	9
80	High concordance of TMPRSS2-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , 2018, 16, 6238-6244.	1.8	3
81	Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-8.	1.4	8
82	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 504-512.	2.8	35
83	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018, 74, 376-386.	1.9	58
84	Î² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. <i>Human Pathology</i> , 2017, 61, 210-220.	2.0	23
85	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , 2017, 19, 279-287.	5.3	16
86	Prevalence of Î²III-tubulin (TUBB3) expression in human normal tissues and cancers. <i>Tumor Biology</i> , 2017, 39, 101042831771216.	1.8	51
87	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , 2017, 38, 1180-1187.	2.8	15
88	High-Level Î³-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 286.	4.1	30
89	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2017, 8, 31494-31508.	1.8	10
90	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , 2017, 8, 108923-108935.	1.8	26

#	ARTICLE	IF	CITATIONS
91	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , 2016, 76, 259-272.	2.3	27
92	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. <i>BMC Cancer</i> , 2016, 16, 641.	2.6	24
93	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , 2016, 138, 1199-1206.	5.1	30
94	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , 2016, 69, 592-598.	1.9	212
95	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , 2016, 48, 102-110.	2.0	18
96	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. <i>Oncotarget</i> , 2016, 7, 3897-3904.	1.8	8
97	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. <i>International Journal of Cancer</i> , 2015, 137, 2354-2363.	5.1	39
98	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , 2015, 10, e0128525.	2.5	26
99	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0134614.	2.5	16
100	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. <i>Oncotarget</i> , 2015, 6, 12822-12834.	1.8	34
101	Heterogeneity in D ^{x3} Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 329.e13-329.e19.	1.6	37
102	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , 2015, 34, 1211-1220.	2.6	12
103	Î²III-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1561-1569.	2.2	14
104	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8591-8606.	4.1	4
105	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2015, 98, 419-426.	2.1	26
106	Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. <i>Human Pathology</i> , 2015, 46, 514-523.	2.0	10
107	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , 2015, 15, 538.	2.6	30
108	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3471-3479.	7.0	43

#	ARTICLE	IF	CITATIONS
109	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS ONE, 2015, 10, e0141867.	2.5	16
110	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget, 2015, 6, 8377-8387.	1.8	44
111	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget, 2015, 6, 27966-27979.	1.8	30
112	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	5.5	69
113	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel, Switzerland), 2014, 3, 137-158.	1.4	2
114	βIII-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	3.8	48
115	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. European Journal of Cancer, 2014, 50, 852-861.	2.8	34
116	Histopathological Characteristics of Buccal Mucosa Transplants in Humans after Engraftment to the Urethra: A Prospective Study. Journal of Urology, 2014, 192, 1725-1729.	0.4	28
117	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	1.9	54
118	A Tertiary Gleason Pattern in the Prostatectomy Specimen and its Association with Adverse Outcome after Radical Prostatectomy. Journal of Urology, 2014, 192, 97-102.	0.4	34
119	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Research, 2014, 34, 2255-61.	1.1	28
120	MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. International Journal of Cancer, 2013, 133, 920-928.	5.1	55
121	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.. Journal of Clinical Oncology, 2013, 31, 5043-5043.	1.6	2
122	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	1.6	3